Antibodies for COVID-19
Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of COVID-19, several of which were validated using virus-infected cell lysates.
Explore the collections of COVID-19 Antibodies, Detection Kits.
FICD
State-of-the art technologies helping to deliver guaranteed Fab, scFv, bi-specific, tribodies, humanized antibodies, and more.
Loading...
FICD
Protein AMPylation, the transfer of AMP from ATP to protein targets, has been recognized as a new mechanism of host-cell disruption by some bacterial effectors that typically contain a FIC-domain. Eukaryotic genomes also encode one FIC-domain protein, HYPE, which has remained poorly characterized.
Recombinant Anti-Human FICD VHH Single Domain Antibody (NABG-064)
-
- Species Reactivity: Human
- Type: Llama VHH
- Application: FC, CA, IP, FuncS
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
© 2007 - 2020 Creative BioLabs All Rights Reserved